232 related articles for article (PubMed ID: 24804929)
1. Teriparatide therapy for denosumab-induced osteonecrosis of the jaw in a male osteoporotic patient.
Neuprez A; Rompen E; Crielaard JM; Reginster JY
Calcif Tissue Int; 2014 Jul; 95(1):94-6. PubMed ID: 24804929
[TBL] [Abstract][Full Text] [Related]
2. Teriparatide therapy for osteonecrosis of the jaw.
Chtioui H; Lamine F; Daghfous R
N Engl J Med; 2011 Mar; 364(11):1081-2; author reply 1082. PubMed ID: 21410382
[No Abstract] [Full Text] [Related]
3. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw.
Cheung A; Seeman E
N Engl J Med; 2010 Dec; 363(25):2473-4. PubMed ID: 20950167
[No Abstract] [Full Text] [Related]
4. [Possible denosumab-induced jaw osteonecrosis in the treatment of osteoporosis. A case report].
Selvi Sabater P; Rizo Cerdá AM; Titos Arcos JC; Espuny Miró A
Farm Hosp; 2014 May; 38(3):248-9. PubMed ID: 24951910
[TBL] [Abstract][Full Text] [Related]
5. Teriparatide for bone loss in the jaw.
Grey A
N Engl J Med; 2010 Dec; 363(25):2458-9. PubMed ID: 20950165
[No Abstract] [Full Text] [Related]
6. More on the resolution of bisphosphonate-associated osteonecrosis of the jaw.
Tsai KY; Huang CS; Huang GM; Yu CT
J Rheumatol; 2010 Mar; 37(3):675; author reply 676. PubMed ID: 20197569
[No Abstract] [Full Text] [Related]
7. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy.
Rachner TD; Platzbecker U; Felsenberg D; Hofbauer LC
Mayo Clin Proc; 2013 Apr; 88(4):418-9. PubMed ID: 23541016
[TBL] [Abstract][Full Text] [Related]
8. Are there any alternatives to alendronate (Fosamax) for osteoporosis to avoid the risk of osteonecrosis of the jaw?
Wynn RL
Gen Dent; 2007; 55(6):495-8. PubMed ID: 18050572
[No Abstract] [Full Text] [Related]
9. Glucocorticoid-induced osteoporosis and osteonecrosis.
Weinstein RS
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):595-611. PubMed ID: 22877431
[TBL] [Abstract][Full Text] [Related]
10. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
[TBL] [Abstract][Full Text] [Related]
11. Study investigates novel approach to bone loss in the jaw.
Garg A; Guez G
Dent Implantol Update; 2011 Feb; 22(2):9-15. PubMed ID: 21425753
[No Abstract] [Full Text] [Related]
12. Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab.
Neuprez A; Coste S; Rompen E; Crielaard JM; Reginster JY
Osteoporos Int; 2014 Jan; 25(1):393-5. PubMed ID: 23835864
[TBL] [Abstract][Full Text] [Related]
13. Review of current literature and implications of RANKL inhibitors for oral health care providers.
Epstein MS; Ephros HD; Epstein JB
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Dec; 116(6):e437-42. PubMed ID: 22901640
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report.
Narongroeknawin P; Danila MI; Humphreys LG; Barasch A; Curtis JR
Spec Care Dentist; 2010; 30(2):77-82. PubMed ID: 20415805
[TBL] [Abstract][Full Text] [Related]
15. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
16. Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis.
Lewiecki EM; Miller PD; Harris ST; Bauer DC; Davison KS; Dian L; Hanley DA; McClung MR; Yuen CK; Kendler DL
J Clin Densitom; 2014; 17(4):490-5. PubMed ID: 24206867
[TBL] [Abstract][Full Text] [Related]
17. Teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw in an elderly Japanese woman with severe osteoporosis.
Iwamoto J; Yago K; Sato Y; Matsumoto H
Clin Drug Investig; 2012 Aug; 32(8):547-53. PubMed ID: 22734599
[TBL] [Abstract][Full Text] [Related]
18. Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings.
Kakehashi H; Ando T; Minamizato T; Nakatani Y; Kawasaki T; Ikeda H; Kuroshima S; Kawakami A; Asahina I
Int J Oral Maxillofac Surg; 2015 Dec; 44(12):1558-64. PubMed ID: 26304604
[TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.
Owosho AA; Blanchard A; Levi L; Kadempour A; Rosenberg H; Yom SK; Farooki A; Fornier M; Huryn JM; Estilo CL
J Craniomaxillofac Surg; 2016 Mar; 44(3):265-70. PubMed ID: 26782845
[TBL] [Abstract][Full Text] [Related]
20. Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy.
Lau AN; Adachi JD
J Rheumatol; 2009 Aug; 36(8):1835-7. PubMed ID: 19671824
[No Abstract] [Full Text] [Related]
[Next] [New Search]
